MedTrace Logo

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

NCT02711345 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2019-09-19

Study results available
· View outcomes & findings →

Summary

A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.

Conditions

  • Ovarian Neoplasms
  • Non-Small-Cell Lung Carcinoma
  • Melanoma
  • Other Solid Tumors

Interventions

DRUG

LTT462

ERK Inhibitor

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-15
Primary Completion
2018-11-21
Completion
2018-11-21
FDA Drug
Yes

Countries

  • United States
  • Germany
  • Japan
  • Singapore
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02711345 on ClinicalTrials.gov